47 related articles for article (PubMed ID: 38523292)
21. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
22. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
[TBL] [Abstract][Full Text] [Related]
23. Significant association of catechol-O-methyltransferase Val158Met polymorphism with bladder cancer instead of prostate and kidney cancer.
Chen Y; Yu X; Li T; Yan H; Mo Z
Int J Biol Markers; 2016 May; 31(2):e110-7. PubMed ID: 27055785
[TBL] [Abstract][Full Text] [Related]
24. Incidence of kidney, bladder, and prostate cancers in Korea: An update.
Song W; Jeon HG
Korean J Urol; 2015 Jun; 56(6):422-8. PubMed ID: 26078838
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.
Huang HB; Jiang SC; Han J; Cheng QS; Dong CB; Pan CM
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1067-73. PubMed ID: 24525705
[TBL] [Abstract][Full Text] [Related]
26. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
Aveta A; Cilio S; Contieri R; Spena G; Napolitano L; Manfredi C; Franco A; Crocerossa F; Cerrato C; Ferro M; Del Giudice F; Verze P; Lasorsa F; Salonia A; Nair R; Walz J; Lucarelli G; Pandolfo SD
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446024
[TBL] [Abstract][Full Text] [Related]
27. Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.
Urquidi V; Rosser CJ; Goodison S
Curr Med Chem; 2012; 19(22):3653-63. PubMed ID: 22680923
[TBL] [Abstract][Full Text] [Related]
28. [Multiple urologic tumors in autopsy material].
Tiszlavicz L; Szalay I
Orv Hetil; 1993 Mar; 134(11):577-81. PubMed ID: 8446411
[TBL] [Abstract][Full Text] [Related]
29. Urine microRNAs as potential noninvasive biomarkers in urologic cancers.
Mlcochova H; Hezova R; Stanik M; Slaby O
Urol Oncol; 2014 Jan; 32(1):41.e1-9. PubMed ID: 24035473
[TBL] [Abstract][Full Text] [Related]
30. Incidence of urological cancers in neurological patients: a review of the literature from the EAU Young Academic Urologist Functional Group.
Cancrini F; Osman N; Doizi S; Guillot-Tantay C; Hüsch T; Illiano E; Tutolo M; Tienza A; Culha MG; Vale L; Raison N; Herve F; Grande P; Roupret M; Phé V
Minerva Urol Nephrol; 2023 Apr; 75(2):163-171. PubMed ID: 36999836
[TBL] [Abstract][Full Text] [Related]
31. Urologic cancer in Thailand.
Lojanapiwat B
Jpn J Clin Oncol; 2015 Nov; 45(11):1007-15. PubMed ID: 26355159
[TBL] [Abstract][Full Text] [Related]
32. Long noncoding RNA in prostate, bladder, and kidney cancer.
Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
[TBL] [Abstract][Full Text] [Related]
33. [De novo urologic tumors in kidney transplant patients].
Rodríguez Faba O; Breda A; Gausa L; Palou J; Villavicencio H
Actas Urol Esp; 2015 Mar; 39(2):122-7. PubMed ID: 24996779
[TBL] [Abstract][Full Text] [Related]
34. [Tumor suppressor genes in human urological malignancies].
Shuin T; Yao M
Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1073-87. PubMed ID: 7609350
[No Abstract] [Full Text] [Related]
35. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Tang H; Dai Q; Shi W; Zhai S; Song Y; Han J
Diabetologia; 2017 Oct; 60(10):1862-1872. PubMed ID: 28725912
[TBL] [Abstract][Full Text] [Related]
36. Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects.
Song Y; Hu J; Chen Q; Guo J; Zou Y; Zhang W; Chen X; Hu W; Huang P
Gene; 2018 Dec; 679():241-252. PubMed ID: 30195633
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
Schubert M; Junker K; Heinzelmann J
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1673-95. PubMed ID: 26660324
[TBL] [Abstract][Full Text] [Related]
38. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
Tönjes A; Kovacs P
Pharmacogenomics; 2013 May; 14(7):825-33. PubMed ID: 23651029
[TBL] [Abstract][Full Text] [Related]
39. Genetics of urological cancers.
Maher ER
Br Med Bull; 1994 Jul; 50(3):698-707. PubMed ID: 7987649
[TBL] [Abstract][Full Text] [Related]
40. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
